基于CiteSpace的中医药治疗抑郁症的可视化分析

Visualized Analysis on Treating Depression with TCM based on CiteSpace

目的 利用CiteSpace 6.1.R6软件绘制可视化知识图谱,分析、探讨近10年中医药治疗抑郁症的研究现状及未来发展趋势。方法 以中国知网数据库为数据来源,检索2014年1月1日至2023年7月31日中医药治疗抑郁症的相关文献,运用CiteSpace 6.1.R6软件提取纳入文献的篇名、摘要、发表时间、关键词、作者及其所属机构等信息,生成可视化知识图谱并进行量化分析。结果 共纳入734篇文献,整体上近10年发文量逐年增加;涉及361位作者,以许二平为代表的核心作者58位,形成5个核心作者合作团队;发文机构以北京中医药大学为代表,共涉及242家单位,发文量大于3篇的机构共53家;关键词440个,聚类后“针灸”一词在时间线上一直延续至今,近3年突现的关键词为“肠道菌群”和“网络药理学”。结论 中医药治疗抑郁症的研究热点主要集中在脑卒中后抑郁(post-stroke depression, PSD)和针灸,研究趋势逐渐转变为以肠道菌群为新靶点或结合网络药理学研究其作用机制和临床效应。

Objective To draw a visualized knowledge map by using CiteSpace6.1.R6 software,and to analyze and discuss the research status of treating depression with TCM in the past 10 years and its future development trend.Methods Using CNKI database as the data source,the related literature on treating depression with traditional Chinese medicine from January 1,2014 to July 31,2023 were searched.CiteSpace6.1.R6 software was used to pick up the information of titles,abstracts,publication time,keywords,authors and their affiliated institutions to generate a visualized knowledge map,and perform quantitative analyses.Results A total of 734 papers had been included,and the number of publications increased year by year in the past decade,involving 361 authors and 58 core authors represented by Xu Erping,forming 5 core author cooperation teams.The publishing organization,represented by Beijing University of Chinese Medicine,involves 242 units,among which there are 53 institutions having published more than 3 articles.There are 440 keywords,among which the term"acupuncture"continued in timeline,and in the past three years,key words"intestinal flora"and"network pharmacology"emerged.Conclusion The research hotspot on treating depression with TCM is mainly focused on Post-Stroke Depression(PSD),and acupuncture and moxibustion.The research trend gradually changed to take intestinal flora as a new target or combine network pharmacology to study its mechanism of action and clinical effects of network pharmacology.